A phase 2a study assessing the efficacy and safety of STN1010905 ophthalmic suspension in subjects with MGD

JRCT ID: jRCT2031240171

Registered date:18/06/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: MGD (Meibomian Gland Dysfunction)
• Date of first enrollment: 01/07/2024
• Target sample size: 120
• Study type: Interventional

Intervention(s)

- Screening period : Artificial tear (BID, Both eyes)
- Treatment period : High dose STN1010905 ophthalmic suspension, Low dose STN1010905 ophthalmic suspension or Placebo (BID, Both eyes)

Outcome(s)

• Primary Outcome: Evaluation of meibomian gland by idra

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

- Outpatient
- Diagnosed as MGD based on the guideline
- Having ocular symptoms

Exclude criteria

- Ocular disease which needs treatment expect MGD and dry eye
- Requires contact lenses wear during the study
- Any decision by the Investigator to terminate a subject in screening

Related Information

• Primary Sponsor: Migita Yukie